IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Treating patients with multiple myeloma in the real world
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera
Maintenance treatment in multiple myeloma: A new era
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia
Background of the KEYLYNK-007 trial for advanced solid tumours
Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML